Pulmonx Corp
NASDAQ:LUNG
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Pulmonx Corp
NASDAQ:LUNG
|
58.6m USD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
9.5T JPY |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.6B USD |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
30B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
110.7B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.3B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.7B GBP |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
41.4B CNY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6B USD |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
4.1B CHF |
Loading...
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
6.7T KRW |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Pulmonx Corp
Glance View
Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 253 full-time employees. The company went IPO on 2020-10-01. The firm provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solutions include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform, which is designed to treat severe emphysema patients. Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Pulmonx Corp is 73.3%, which is below its 3-year median of 73.7%.
Over the last 3 years, Pulmonx Corp’s Gross Margin has decreased from 74.9% to 73.3%. During this period, it reached a low of 73.1% on Jun 30, 2025 and a high of 74.9% on Sep 30, 2022.
